A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of hCBE-11, a Humanized Monoclonal Antibody, in Subjects With Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors. This is the first study of hCBE-11 in humans and is designed to determine the safety and how well patients tolerate this investigational drug. The study duration is two years with treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and long-term follow-up contact every 3 months thereafter.

Start Date01 Jan 2005

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with hCBE-11

100 Translational Medicine associated with hCBE-11

100 Patents (Medical) associated with hCBE-11

Literatures (Medical) associated with hCBE-11

01 Sep 2013·Microbes and InfectionQ3 · MEDICINE

Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways

Q3 · MEDICINE

Article

Author: Barry T. Rouse ; Eugene Y. Chiang ; Sachin Mulik ; Fernanda Giménez ; Jane L. Grogan ; Tamara Veiga-Parga

Herpes simplex virus 1 infection of the eye can result in stromal keratitis, a chronic immunoinflammatory lesion that is a significant cause of human blindness. A key to controlling the severity of lesions is to identify cellular and molecular events responsible for tissue damage. This report evaluates the role of lymphotoxin-α, a proinflammatory cytokine that could be involved during stromal keratitis. We demonstrate that after infection, both lymphotoxin-α and lymphotoxin-β transcripts are detectable at high levels 48 h postinfection, suggesting roles for the secreted homotrimer lymphotoxin-α3 and the membrane-bound lymphotoxin-α1β2 heterotrimer in stromal keratitis. Using a corneal stromal fibroblast cell line, lymphotoxin-α3 and lymphotoxin-α1β2 were found to have proinflammatory roles by stimulating production of chemokines. Treatment of mice with a depleting anti-lymphotoxin-α mAb during the clinical phase of the disease significantly attenuated stromal keratitis lesions. In treated mice, expression of proinflammatory molecules and chemokines was reduced, as were numbers of cornea-infiltrating proinflammatory cells, particularly Th1 cells. The protective effect of anti-lymphotoxin-α mAb was highly reduced with a mutant version of the mAb that lacks Fc receptor binding activity, indicating that depletion of lymphotoxin-expressing cells was mainly responsible for efficacy, with LT-α3 contributing minimally to inflammation. These data demonstrate that lymphotoxin-expressing cells, such as Th1 cells, mediate stromal keratitis.

01 Oct 1997·American Journal of Clinical PathologyQ4 · MEDICINE

erbB-2 Oncoprotein Expression in Breast Carcinoma:Poor Prognosis Associated With High Degree of Cytoplasmic Positivity Using CB-11 Antibody

Q4 · MEDICINE

Article

Author: Albert A. Keshgegian ; Avital Cnaan

The relationship between immunohistochemically measured membranous expression of erbB-2 oncoprotein and prognosis in breast cancer is controversial, and the relationship between cytoplasmic positivity and prognosis has been minimally investigated. The clinical course of 300 women with infiltrating breast carcinoma, whose tumors were stained for erbB-2 oncoprotein with CB-11 monoclonal antibody, was followed for 5 to 79 months (median, 41 months). Higher numbers of cancer-related deaths were observed in patients with moderate-to-strong cytoplasmic positivity (15/60, 25%) and strong membranous positivity (9/29, 31%) than in patients with negatively stained tumors (8/53, 15%) or tumors with weaker degrees of cytoplasmic or membranous positivity (rate similar to or less than negative tumors). Relapse-free survival was also significantly shorter in patients with tumors with strong membranous positivity and moderate-to-strong cytoplasmic positivity; much of the latter relationship was due to a high number of patients who had erbB-2-positive tumors and who were never disease free. A significant association between decreased relapse-free survival and moderate-to-strong cytoplasmic (but not membranous) positivity persisted even after correction for other variables associated with poor outcome (histologic grade, tumor size, lymph node involvement, and hormone receptor status). Moderate-to-strong erbB-2 oncoprotein cytoplasmic positivity, measured with CB-11 antibody, is associated with a poor prognosis and seems to have biologic significance.

01 Feb 1988·Japanese Journal of Cancer Research

EFFECT OF CULTURE SUPERNATANT OF MT‐2 CELLS ON HUMAN IMMUNODEFICIENCY VIRUS‐PRODUCING CELLS, MOLT‐4/HIV_HTLV‐IIIB CELLS

Article

Author: Yasuji Kido ; Toshifumi Matsuyama ; Tsutomu Yoshida ; Yoshiaki Hamamoto ; Naoki Yamamoto ; Susumu Kobayashi ; Nobuyuki Kobayashi

The effect of culture supernatant of MT‐2 cells on human immunodeficiency virus (HIV)‐producing cells, MOLT‐4/HIVHTLV‐IIIB cells, was examined. As compared to the effect on MOLT‐4 cells, parent cells not infected with HIV, a selective cytotoxic/cytostatic effect on MOLT‐4/ HIVHTLV‐IIIB cells was observed 4 days after treatment with up to 640‐fold‐diluted MT‐2 supernatant. Furthermore, under similar conditions, a 2‐ to 6‐fold increase in the number of HIV particles was detected in the culture of MOLT‐4/HIVHTLV‐IIIB cells 6 hr after treatment. Complete blocking of these effects by anti‐lymphotoxin monoclonal antibody, but not by anti‐tumor necrosis factor antibody, indicates that these effects of MT‐2 supernatant on MOLT‐4/HIVHTLV‐IIIB cells are attributable to a lymphotoxin‐related cytotoxic factor.

100 Deals associated with hCBE-11

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rectal Cancer	Preclinical	US	Biogen, Inc.	03 Oct 2006
Advanced Malignant Solid Neoplasm	Preclinical	US	Biogen, Inc.	01 Jan 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

hCBE-11

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation